Overall rank by patents
#26,778
of 49,997 tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 11 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Lumiphore ranks #26,778 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 11 technology areas.
USPTO PatentsView assignee plate
Corpus R26778 · US Corporation #26,778 · 10 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL
Nearest grant-volume peer: LTC Co., Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Lumiphore · this assignee
42 score
3D Lighting… · lowest
7 score
What this shows Lumiphore's Innovation Score is 41.6/100 (top 33% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Lumiphore, Inc. is a focused PatentsView assignee: 11 CPC subclasses with 90% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2016. By volume, Lumiphore sits between LTC Co., Ltd. and Lytix Biopharma AS.
Lumiphore, Inc. shows 4 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
LTC Co., Ltd.
10 patents
LTI Flexible Products, Inc.
10 patents
Lumen Devices, LLC.
10 patents
Lumenpulse Group Inc.
10 patents
Lumlux Corp.
10 patents
Luxium Solutions, LLC
10 patents
Lynk Pharmaceuticals Co. Ltd.
10 patents
Lytix Biopharma AS
10 patents
Lumiphore, Inc.
10 patents
What this shows Lumiphore holds 10 patents at rank #26,740, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #26,740 in granted patent volume.
Other assignees with the most granted patents in Lumiphore's primary technology class.
Lumiphore's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
42 Top 33% higher than 67% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 10.0% |
| 2018 | 1 | 10.0% |
| 2019 | 4 | 40.0% |
| 2022 | 1 | 10.0% |
| 2023 | 2 | 20.0% |
| 2024 | 1 | 10.0% |
Top 11 of 11 technology areas
Overall rank by patents
#26,778
of 49,997 tracked assignees
41.6 out of 100
What to do with this data
Lumiphore, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.